Pfizer and Flagship Expand Collaboration with Focus on Obesity and Lung Cancer Initiatives

Pfizer and Flagship Pioneering have expanded their strategic partnership with new initiatives focused on addressing obesity and lung cancer through their collaboration with two Flagship-founded biotech companies[1]. These collaborations involve the innovative efforts of Ampersand Biomedicines, which is employing its Address, Navigate, Determine (AND) platform to develop biologic medicines for obesity by targeting tissue-specific metabolic pathways[2]. Meanwhile, Montai Therapeutics is exploring small molecule discoveries aimed at inhibiting cancer cell growth as part of their lung cancer initiative[1]. These ventures are the latest in Pfizer's extended agreement with Flagship to leverage bioplatform innovations for drug development, marking an important step in tackling unmet medical needs[2].